Aileron Therapeutics (NASDAQ:ALRN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm presently has a $1.25 target price on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 9.65% from the stock’s current price.
According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. “
Separately, ValuEngine upgraded Aileron Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
Aileron Therapeutics stock opened at $1.14 on Tuesday. The company has a current ratio of 4.23, a quick ratio of 4.23 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $15.30 million, a price-to-earnings ratio of -0.64 and a beta of 2.14. Aileron Therapeutics has a 52 week low of $0.52 and a 52 week high of $10.23.
Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.08. Research analysts anticipate that Aileron Therapeutics will post -2.15 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in ALRN. Paloma Partners Management Co bought a new stake in shares of Aileron Therapeutics during the second quarter worth $140,000. Millennium Management LLC raised its position in shares of Aileron Therapeutics by 565.4% during the second quarter. Millennium Management LLC now owns 123,658 shares of the company’s stock worth $670,000 after acquiring an additional 105,073 shares during the last quarter. Parkwood LLC bought a new stake in shares of Aileron Therapeutics during the third quarter worth $149,000. Bridgeway Capital Management Inc. raised its position in shares of Aileron Therapeutics by 78.6% during the third quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock worth $312,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Aileron Therapeutics during the third quarter worth $137,000. Institutional investors own 12.72% of the company’s stock.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Featured Story: How Do You Calculate Return on Investment (ROI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.